Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 5/20 | 0.63 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.63 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.56 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.56 |
| ▸ | PTGS2 | P35354 | 7/20 | 0.55 |
| ▸ | PTGS1 | P23219 | 3/20 | 0.54 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.50 |
| ▸ | LMNA | P02545 | 2/20 | 0.50 |
| ▸ | TEAD4 | Q15561 | 1/20 | 0.50 |
| ▸ | GAA | P10253 | 1/20 | 0.50 |
| ▸ | POLB | P06746 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
| ▸ | GFER | P55789 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13814624 | 1.00 | HTT (0.63) | HTTSMN1; SMN2TDP1L3MBTL1PTGS2 | |
| SCHEMBL2758532 | 0.94 | PTGS2 (0.58) | HTTSMN1; SMN2TDP1L3MBTL1PTGS2 | |
| SCHEMBL19105488 | 0.94 | HTT (0.73) | HTTSMN1; SMN2TDP1L3MBTL1PTGS2 | |
| SCHEMBL20149706 | 0.94 | PTGS2 (0.58) | HTTSMN1; SMN2TDP1L3MBTL1PTGS2 | |
| SCHEMBL12708896 | 0.94 | PTGS2 (0.58) | HTTSMN1; SMN2TDP1L3MBTL1PTGS2 | |
| SCHEMBL23153426 | 0.94 | HTT (0.73) | HTTSMN1; SMN2TDP1L3MBTL1PTGS2 | |
| SCHEMBL10016733 | 0.94 | HTT (0.73) | HTTSMN1; SMN2TDP1L3MBTL1PTGS2 | |
| SCHEMBL11547843 | 0.91 | HTT (0.58) | HTTSMN1; SMN2PTGS2PTGS1ALDH1A1 | |
| SCHEMBL19341781 | 0.89 | HTT (0.53) | HTTSMN1; SMN2TDP1L3MBTL1PTGS2 | |
| SCHEMBL9888806 | 0.89 | HTT (0.67) | HTTSMN1; SMN2TDP1L3MBTL1PTGS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 80 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240226816-A1 | CO2 GAS ENRICHMENT METHOD | KING FAHD UNIVERSITY OF PETROLEUM AND MINERALS (SA) | 2024-07-11 | — | — | US | disclosed |
| US-20240207543-A1 | COATING PROCESS | JPMORGAN CHASE BANK, N.A. | 2024-06-27 | — | — | US | disclosed |
| US-20240207543-A1 | COATING PROCESS | JPMORGAN CHASE BANK, N.A. | 2024-06-27 | — | — | US | disclosed |
| US-11779716-B2 | Method for making medicinal delivery device having multi-layer coating | KINDEVA DRUG DELIVERY L.P. (US) | 2023-10-10 | — | — | US | disclosed |
| US-20230173434-A1 | METHOD FOR SEPARATING A GAS MIXTURE | KING FAHD UNIVERSITY OF PETROLEUM AND MINERALS (SA) | 2023-06-08 | — | — | US | disclosed |
| US-20230157996-A1 | SMALL-MOLECULE INHIBITOR TARGETING EB VIRUS NUCLEAR ANTIGEN PROTEIN, PREPARATION METHOD AND USE THEREOF | Shenzhen Bay Laboratory (CN) | 2023-05-25 | — | — | US | disclosed |
| US-20230149860-A1 | GAS FILTER FOR SEPARATING GASEOUS COMPOSITIONS | KING FAHD UNIVERSITY OF PETROLEUM AND MINERALS (SA) | 2023-05-18 | — | — | US | disclosed |
| EP-2843743-B1 | Membrane electrode units for high temperature fuel cells with improved stability | BASF SE (DE) | 2018-03-28 | — | — | EP | disclosed |
| EP-2871180-B1 | 2-AMINONICOTINIC ACID ESTER DERIVATIVE AND BACTERICIDE CONTAINING SAME AS ACTIVE INGREDIENT | AGRO KANESHO CO LTD (JP) | 2018-03-21 | — | — | EP | disclosed |
| US-20170266652-A1 | FUNCTIONALIZED MAIN CHAIN POLYMERS | HÄRING THOMAS (DE) | 2017-09-21 | — | — | US | disclosed |
| US-20080027061-A1 | omega-Carboxy Aryl Substituted Diphenyl Ureas As p38 Kinase Inhibitors | BAYER HEALTHCARE LLC | 2008-01-31 | — | — | US | disclosed |
| EP-1636585-B1 | DIARYL UREAS WITH KINASE INHIBITING ACTIVITY | BAYER PHARMACEUTICALS CORP (US) | 2008-01-16 | — | — | EP | disclosed |
| US-20070244120-A1 | INHIBITION OF RAF KINASE USING SUBSTITUTED HETEROCYCLIC UREAS | BAYER HEALTHCARE LLC | 2007-10-18 | — | — | US | disclosed |
| US-20070244120-A1 | INHIBITION OF RAF KINASE USING SUBSTITUTED HETEROCYCLIC UREAS | BAYER HEALTHCARE LLC | 2007-10-18 | — | — | US | disclosed |
| US-7235576-B1 | Omega-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors | BAYER PHARMACEUTICALS CORPORATION (US) | 2007-06-26 | — | — | US | disclosed |
| US-7235576-B1 | Omega-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors | BAYER PHARMACEUTICALS CORPORATION (US) | 2007-06-26 | — | — | US | disclosed |
| WO-2007053574-A2 | COMBINATIONS COMPRISING SORAFENIB AND INTERFERON FOR THE TREATMENT OF CANCER | BAYER PHARMACEUTICALS CORPORATION (US) | 2007-05-10 | — | — | WO | disclosed |
| US-20070020704-A1 | Diaryl ureas with kinase inhibiting activity | BAYER HEALTHCARE LLC | 2007-01-25 | — | — | US | disclosed |
| US-20070020704-A1 | Diaryl ureas with kinase inhibiting activity | BAYER HEALTHCARE LLC | 2007-01-25 | — | — | US | disclosed |
| US-6294573-B1 | FOR THERAPY RHEUMATOID ARTHRITIS, OSTEOARTHRITIS, OSTEOPENIAS SUCH AS OSTEOPOROSIS, PERIODONTITIS, GINGIVITIS, CORNEAL, EPIDERMAL OR GASTRIC ULCERATION, AND TUMOR GROWTH AND METASTASIS OR INVASION | ABBOTT LABORATORIES | 2001-09-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230157996-A1 | SMALL-MOLECULE INHIBITOR TARGETING EB VIRUS NUCLEAR ANTIGEN PROTEIN, PREPARATION METHOD AND USE THEREOF | SSB, EBNA1BP2, PML | HTT 3116/4885SMN1; SMN2 2894/4885TDP1 2118/4885 |
| US-20070020704-A1 | Diaryl ureas with kinase inhibiting activity | FLT4, FLT1, FLT3 | HTT 1957/4885SMN1; SMN2 4039/4885TDP1 946/4885 |
| US-20080027061-A1 | omega-Carboxy Aryl Substituted Diphenyl Ureas As p38 Kinase Inhibitors | MAPK1, MAPK8, MAPK3 | HTT 3241/4885SMN1; SMN2 2811/4885TDP1 2039/4885 |
| US-20070244120-A1 | INHIBITION OF RAF KINASE USING SUBSTITUTED HETEROCYCLIC UREAS | BRAF, RAF1, ARAF | HTT 3520/4885SMN1; SMN2 4560/4885TDP1 2205/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.